Cartesian Therapeutics Inc. | Small-cap | Healthcare
$10.76
3.86%
| Cartesian Stock Comparison:
Cartesian vs VertexCartesian vs RegeneronCartesian vs Alpha Tau MedicalCartesian vs Foghorn TherapeuticsCartesian vs Tevogen Bio HoldingsCartesian vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 38.9M
Operating Income -36.3M -93.33%
Net Income -77.4M -198.97%

Balance Sheet Metrics

Total Assets 435.0M
Total Liabilities 441.8M
Shareholders Equity -6.8M

Cash Flow Metrics

Operating Cash Flow -30.9M
Free Cash Flow -32.8M

Revenue & Profitability Trend

Cartesian Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 38.9M 26.0M 110.8M 85.1M 16.6M
Cost of Goods Sold - - - - -
Gross Profit - - - - -
Operating Expenses 75.2M 112.4M 96.2M 89.7M 73.4M
Operating Income -36.3M -86.4M 14.5M -4.6M -56.8M
Pre-tax Income -77.1M -238.7M 34.8M -9.7M -68.9M
Income Tax 287.0K -19.0M -609.0K 16.0M 0
Net Income -77.4M -219.7M 35.4M -25.7M -68.9M
EPS (Diluted) - -$49.80 $3.00 -$6.60 -$20.40

Income Statement Trend

Cartesian Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 216.6M 90.7M 148.1M 144.4M 151.3M
Non-Current Assets 218.4M 214.3M 17.7M 15.4M 14.1M
Total Assets 435.0M 305.0M 165.9M 159.9M 165.4M
Liabilities
Current Liabilities 23.0M 68.2M 25.1M 72.3M 81.5M
Non-Current Liabilities 418.8M 677.0M 47.0M 65.1M 101.9M
Total Liabilities 441.8M 745.2M 72.1M 137.4M 183.4M
Equity
Total Shareholders Equity -6.8M -440.2M 93.8M 22.5M -18.0M

Balance Sheet Composition

Cartesian Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -77.4M -219.7M 35.4M -25.7M -68.9M
Operating Cash Flow -30.9M -185.8M -14.3M -63.0M 31.2M
Investing Activities
Capital Expenditures -8.7M -206.0K -1.2M -1.1M -741.0K
Investing Cash Flow -8.7M 34.6M -15.0M -17.1M -741.0K
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow 164.4M -13.4M 38.9M 52.0M 13.1M
Free Cash Flow -32.8M -51.4M -32.8M -61.5M 34.1M

Cash Flow Trend

Cartesian Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 1.81
Forward P/E -2.76
Price to Book -12.32
Price to Sales 7.32
PEG Ratio -2.76

Profitability Ratios

Profit Margin -112.11%
Operating Margin -1,989.91%
Return on Equity 1,138.25%
Return on Assets -7.55%

Financial Health

Current Ratio 12.34
Debt to Equity -0.65

Per Share Data

EPS (TTM) $5.33
Book Value per Share -$0.84
Revenue per Share $1.53

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
rnac 250.0M 1.81 -12.32 1,138.25% -112.11% -0.65
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alpha Tau Medical 245.6M - 3.63 -47.95% 0.00% 21.83
Foghorn Therapeutics 272.6M - -5.07 190.26% 0.00% -0.57
Tevogen Bio Holdings 222.5M 2.86 -24.67 205.68% 0.00% -0.62

Financial data is updated regularly. All figures are in the company's reporting currency.